| pubmed-article:5511930 | pubmed:otherAbstract | PIP: 116 women aged 21-35 years were divided into 2 groups by parity. The low-parity group was given 150 mg medroxyprogesterone acetate (Depo-Provera) each trimester (Group 150), and the high-parity group was given 400 mg each semester (Group 400). There was 1 pregnancy in the latter group 5-1/2 months after the injection. After discontinuation, 1 patient in Group 150 became pregnant a month after the period of theoretical effectiveness, and 1 patient in Group 200 2 months after. After 15 months there were 11 (21%) dropouts in Group 150 and 2 (4.6%) in Group 400. This was attributed to the fact that most side effects occurred in the 2nd and 3rd months, which coincided with the trimester injections, but not with the semester injections. Metrorrhagia was the main side effect. Examinations revealed lowered levels of urinary estrogens and pregnanediol, endometrial atrophy especially in Group 400, and a karyopyknotic index that was lower for Group 150 but higher for Gr oup 400. No cholestatic process was found. 10% of the subjects showed slight weight loss. Until further studies of recovery of function have been done, the 400 mg dose should be reserved for those who have had the number of children desired of for whom pregnancy is absolutely contraindicated. | lld:pubmed |
